Steatohepatitis: Understanding Your Pathology Report

by Stephanie Reid, MD FRCPC
November 17, 2026


Print this article

Steatohepatitis is a liver disease in which fat buildup in liver cells is accompanied by inflammation and injury. It is not cancer. It is more serious than fat alone because the ongoing injury can lead to scarring of the liver over time. With treatment of the cause, steatohepatitis can improve, and early scarring can partly heal.

This article explains what steatohepatitis means, how pathologists recognize it on a liver biopsy, and what the activity score and fibrosis stage in your report describe. It also explains the newer names, such as MASH, and the treatments now available.

What is steatohepatitis?

The word steatohepatitis joins two parts. “Steato” means fat, and “hepatitis” means inflammation of the liver. In steatosis, liver cells called hepatocytes store too much fat but are otherwise healthy. In steatohepatitis, the fat is accompanied by signs that the cells are being damaged and that the body is reacting to that damage.

When liver cells are injured repeatedly, the liver tries to repair itself by laying down scar tissue, called fibrosis. If the injury continues for many years, the scarring can spread across the liver and lead to cirrhosis. This is why doctors pay close attention to steatohepatitis even when a person feels well.

What are the types of steatohepatitis?

Steatohepatitis is named by its cause. The names changed in 2023, when international liver societies agreed on new terms, so your report may use either the older or the newer name.

  • Metabolic dysfunction-associated steatohepatitis (MASH). This is the most common type. It occurs in people with metabolic risk factors, most often excess weight and type 2 diabetes. MASH replaces the older name, nonalcoholic steatohepatitis (NASH).
  • Alcohol-related steatohepatitis (ASH). This type is caused mainly by heavy, long-term alcohol use. It was previously called alcoholic steatohepatitis.
  • MetALD. This name is used when a person has metabolic risk factors and also drinks a moderate amount of alcohol, so both causes play a part.
  • Drug-related steatohepatitis. A small number of medications can cause steatohepatitis. Examples include amiodarone, methotrexate, and tamoxifen. Irinotecan, a chemotherapy drug, can cause it in people treated for cancer that has spread to the liver.

Our article on steatosis lists the full set of new names and the risk factors used to define them.

What are the symptoms of steatohepatitis?

Most people with steatohepatitis have no symptoms until the liver is badly scarred. The condition is often suspected because of raised liver enzymes on a liver blood test panel or a fatty liver seen on an ultrasound. Some people feel tired or have discomfort in the upper right side of the abdomen.

When cirrhosis develops, symptoms can include yellowing of the skin and eyes, called jaundice, swelling of the legs or abdomen, and easy bruising. Severe alcohol-related steatohepatitis can also cause a sudden illness called alcohol-associated hepatitis, with jaundice that comes on quickly and can lead to liver failure.

How is the diagnosis made?

Steatohepatitis can only be confirmed by examining liver tissue under a microscope. Blood tests and scans that measure liver stiffness can estimate how much scarring is present, and many people are now managed with these tests alone. A liver biopsy is done when the diagnosis is uncertain, when another liver disease may also be present, or when the amount of scarring will change treatment.

During a needle biopsy, a thin core of liver tissue is removed and sent to a pathologist. The pathologist determines whether steatohepatitis is present by assessing the overall pattern of injury, not by adding up a score. A trichrome stain, which colors scar tissue blue, is used to judge the amount of fibrosis. An iron stain is often added to detect excess iron.

Microscopic features of steatohepatitis

Steatohepatitis is diagnosed when the pathologist sees a characteristic group of changes. In adults, these changes usually begin around the small veins in the center of each liver unit, an area pathologists call zone 3. Your report may describe some or all of the following features:

  • Steatosis. Fat droplets fill many of the liver cells. We grade the amount from 0 to 3, and our article on steatosis explains these grades.
  • Ballooning. Ballooned hepatocytes are injured liver cells that have swollen and become pale and wispy inside. Ballooning is the key feature that separates steatohepatitis from steatosis.
  • Lobular inflammation. Small clusters of inflammatory cells sit among the liver cells. Pathologists count these clusters to score inflammation.
  • Mallory-Denk bodies. Mallory-Denk bodies are pink, rope-like clumps of damaged protein inside injured cells. Older reports may call them Mallory bodies or Mallory hyaline.
  • Apoptotic hepatocytes. These are liver cells that have died through apoptosis, a controlled form of cell death. They are also called acidophil bodies.
  • Pericellular fibrosis. Fine strands of scar tissue wrap around individual liver cells in zone 3. This pattern is sometimes called chicken-wire fibrosis because of how it looks on a trichrome stain.

In children, steatohepatitis often looks different. The scarring tends to start around the portal tracts rather than in zone 3. Portal tracts are the small channels that carry blood vessels and bile ducts through the liver.

Can a pathologist tell alcohol-related from metabolic steatohepatitis?

Alcohol-related steatohepatitis and metabolic steatohepatitis look very similar under the microscope. A pathologist usually cannot be sure of the cause from the biopsy alone. Your doctor makes the final decision by combining the biopsy with your medical history, alcohol use, and blood tests.

Some features are more common with alcohol, and the report may mention them:

  • Neutrophil-rich inflammation. Neutrophils are inflammatory cells that are more common in alcohol-related disease. When they surround a ballooned cell, the pattern is called satellitosis.
  • Many Mallory-Denk bodies. Mallory-Denk bodies are seen in both types but tend to be larger and more numerous with alcohol.
  • Sclerosing hyaline necrosis. Dense scarring closes off the small veins in zone 3. This change is typical of heavy alcohol use.
  • Bile build-up. Cholestasis, or backed-up bile, is more often seen in severe alcohol-related disease.

NAFLD activity score (NAS)

Many pathologists give a NAFLD activity score, also called NAS or the activity grade, when steatohepatitis is diagnosed. The NASH Clinical Research Network developed the score in 2005. The name may change in the future to match the new terms, but most reports still use NAS. It adds three separate scores:

  • Steatosis (0 to 3). Based on the percentage of liver tissue that contains fat.
  • Lobular inflammation (0 to 3). Based on the number of inflammatory clusters seen in a standard microscope field. A score of 0 means none, and 3 means more than four clusters per field.
  • Ballooning (0 to 2). A score of 0 means no ballooned cells, 1 means a few, and 2 means many.

The total ranges from 0 to 8. In the original study, scores of 5 or more were seen mostly in biopsies with steatohepatitis, and scores of 0 to 2 were seen mostly in biopsies without it. Scores of 3 or 4 fell in between. The NAS describes how active the disease is today. It does not measure scarring, and it is not used alone to make the diagnosis.

Some pathologists, especially in Europe, use the SAF score instead. SAF stands for steatosis, activity, and fibrosis, and it reports the same features slightly differently.

Fibrosis stage

The fibrosis stage describes how much scarring is present and where it is found. It is the most important finding in a steatohepatitis biopsy because it predicts long-term liver health better than any other feature. Most reports use the NASH Clinical Research Network stages:

  • Stage 0. No fibrosis.
  • Stage 1a. Mild, delicate scarring around the liver cells in zone 3.
  • Stage 1b—moderate, denser scarring around the liver cells in zone 3.
  • Stage 1c. Scarring around the portal tracts only. This pattern is more common in children.
  • Stage 2. Scarring around the liver cells in zone 3 and around the portal tracts.
  • Stage 3. Bridging fibrosis, in which bands of scar tissue connect one part of the liver to another.
  • Stage 4. Cirrhosis, in which scar tissue surrounds nodules of liver cells throughout the liver.

Doctors often group these stages. Stage 2 is called significant or moderate fibrosis, stage 3 is called advanced fibrosis, and stage 4 is cirrhosis. Your report may write the stage as F0 to F4.

Other findings that may be included in your report

  • Adequacy. The report may list the biopsy length or the number of portal tracts. A small or broken-up sample can underestimate the fibrosis stage.
  • Fragmentation. Scarred liver tissue often breaks into small pieces during the biopsy, which can make the fibrosis stage harder to judge.
  • Portal inflammation. Mild inflammation in the portal tracts is common in steatohepatitis. More than mild portal inflammation can suggest a second liver disease.
  • Iron. Some biopsies show extra stored iron. A large amount may prompt blood tests for an inherited iron-overload condition.
  • Bile ducts. Damaged or missing bile ducts are not part of steatohepatitis and suggest another condition.
  • Features of another liver disease. The pathologist will mention changes that suggest a second disease, such as autoimmune hepatitis or viral hepatitis, because both can be present at once.

What does steatohepatitis mean for my health?

Steatohepatitis is a slowly changing disease, and it can move in either direction. A large review of repeat biopsies found that scarring advanced by about one stage every 7 years, on average, in people with steatohepatitis. In people with steatosis alone, the same change took about 14 years. Another analysis found that steatohepatitis went away in about 29% of people over a median of 3.5 years.

The fibrosis stage is the strongest predictor of what happens next. People with no scarring or stage 1 fibrosis have a low risk of serious liver problems over the following decades. The risk rises with stage 3 and is highest with cirrhosis, which can lead to liver failure and hepatocellular carcinoma, a type of liver cancer. People with metabolic steatohepatitis also have a higher risk of heart disease, which is often the bigger threat to their health.

What happens after the diagnosis?

After pathology confirms steatohepatitis, treatment focuses on addressing the cause and stopping scarring from advancing. The fibrosis stage in your report guides how closely your liver is watched and whether medication is considered.

  • Weight loss. For metabolic steatohepatitis, weight loss is the foundation of treatment. Global guidance published in 2025 links 7% to 10% weight loss with less inflammation and 10% or more with improvement in scarring.
  • Alcohol. Stopping alcohol is the most important step in alcohol-related steatohepatitis and MetALD.
  • Heart and metabolic health. Your doctor will also treat diabetes, blood pressure, and cholesterol.
  • Weight-loss surgery. Bariatric surgery may be considered for some people with obesity and steatohepatitis who do not have cirrhosis.

Two medications are approved for adults with metabolic steatohepatitis and stage 2 or 3 fibrosis who do not have cirrhosis. Both are used together with diet and exercise.

  • Resmetirom. This daily tablet acts on the liver to increase fat breakdown. The US Food and Drug Administration (FDA) granted accelerated approval in March 2024. It was authorized in the European Union in August 2025 and by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in June 2026.
  • Semaglutide. This weekly injection is also used for weight loss and diabetes. For steatohepatitis, it received FDA accelerated approval in August 2025 and conditional authorization from Health Canada in November 2025.

These approvals are based on improvements seen on liver biopsies after about one to one and a half years of treatment. Studies of their effect on long-term outcomes, such as cirrhosis and survival, are still under way. Medications are not approved for steatohepatitis without significant scarring, or for steatosis alone.

Most people are followed with blood tests and liver stiffness scans rather than repeat biopsies. A hepatologist, a doctor who specializes in the liver, is often involved when the fibrosis stage is 2 or higher. People with cirrhosis are offered regular ultrasound scans to look for early liver cancer.

Questions to ask your doctor

  • Does my biopsy show steatohepatitis or only steatosis?
  • Do you think my steatohepatitis is metabolic, alcohol-related, or both?
  • What was my NAFLD activity score, and what does it say about my liver?
  • What fibrosis stage was reported?
  • Was the biopsy large enough to stage the fibrosis reliably?
  • Did the report mention features of another liver disease?
  • How much weight loss would help my liver?
  • Should I stop drinking alcohol completely?
  • Am I a candidate for resmetirom or semaglutide?
  • Should I see a hepatologist?
  • Which tests will be used to follow my liver, and how often?
  • Do I need screening for liver cancer?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?